Myasthenia Gravis - Epidemiology Forecast to 2027

Myasthenia Gravis - Epidemiology Forecast to 2027

  • January 2018 •
  • 50 pages •
  • Report ID: 5299592
DelveInsight’s "Myasthenia Gravis - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Myasthenia Gravis epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Myasthenia Gravis Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Myasthenia Gravis in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Myasthenia Gravis outlook. It also includes the explanation of changing trends of epidemiology outlining the Myasthenia Gravis scenario.

Myasthenia Gravis Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Myasthenia Gravis thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Myasthenia Gravis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Myasthenia Gravis Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Myasthenia Gravis

Key assessments
• Patient Segmentation in Myasthenia Gravis
• Myasthenia Gravis Risk & Burden
• Factors driving growth in a specific Myasthenia Gravis patient population